Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 J&J | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

J&J

Worldwide pharmaceutical revenues dropped 14% to $5.2 billion in 3Q09

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

J&J 3Q09

3Q Revenues: $15.1 billion (-5%)

3Q Earnings: $3.3 billion (+1%)

YTD Revenues: $45.3 billion (-7%)

YTD Earnings: $10.0 billion (-2%)

Comments: Worldwide pharmaceutical revenues dropped 14% to $5.2 billion in 3Q09, with currency fluctuation accounting for 2% of that. U.S. pharma revenues dropped 19% to $2.9 billion. For the YTD, worldwide pharma revenues dropped 13% to $16.5 billion (4% from currency), with U.S. drug revenues falling 15% to $9.7 billion. During the quarter, U.S. sales of Topamax fell from $606 million to $72 million. The only major pharmaceutical products to show growth in the quarter were Remicade (+6% to $1.0 billion), Risperdal Consta (+4% to $353 million), and Velcade (+22% to $231 million). New drugs Prezista and Invega were up worldwide 91% to $151 million and 9% to $97 million, respectively.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters